FR5267M - - Google Patents

Info

Publication number
FR5267M
FR5267M FR54286A FR54286A FR5267M FR 5267 M FR5267 M FR 5267M FR 54286 A FR54286 A FR 54286A FR 54286 A FR54286 A FR 54286A FR 5267 M FR5267 M FR 5267M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR54286A
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR5267M publication Critical patent/FR5267M/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR54286A 1965-03-23 1966-03-21 Expired FR5267M (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44220565A 1965-03-23 1965-03-23
US57654966A 1966-09-01 1966-09-01
US734770A 1970-01-28 1970-01-28

Publications (1)

Publication Number Publication Date
FR5267M true FR5267M (enExample) 1967-07-31

Family

ID=27358345

Family Applications (1)

Application Number Title Priority Date Filing Date
FR54286A Expired FR5267M (enExample) 1965-03-23 1966-03-21

Country Status (5)

Country Link
US (1) US3609152A (enExample)
BE (1) BE678216A (enExample)
DE (1) DE1620127C3 (enExample)
FR (1) FR5267M (enExample)
GB (3) GB1062357A (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) * 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4814335A (en) * 1982-12-30 1989-03-21 Biomeasure, Incorporated Antiviral compounds
US4625026A (en) * 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
JPS6442472A (en) * 1987-08-10 1989-02-14 Kanebo Ltd Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
US4877790A (en) * 1987-12-15 1989-10-31 Kanebo Limited Quinazoline derivative, processes for its production, and cerebral dysfunction remedying agent comprising it as active ingredient
TW334434B (en) * 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
AU2769897A (en) * 1996-05-07 1997-11-26 Basf Aktiengesellschaft Imidazoquinazolines, agents containing them and their use to combat fungi and animal pests
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
EP1363899B1 (en) * 2001-01-02 2005-05-11 F.Hoffmann-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
JP4017988B2 (ja) * 2001-05-14 2007-12-05 オムノバ ソリューソンズ インコーポレーティッド ペンダントフッ素化炭素基を有する環状モノマー由来のポリマー界面活性剤
EP1407774A1 (en) * 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
EP1398032A1 (en) * 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
CA2500888C (en) 2002-10-01 2010-07-13 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
WO2005054201A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4864717B2 (ja) 2003-11-20 2012-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての７−フェニルアルキル置換２−キノリノンおよび２−キノキサリノン
EP1771175B1 (en) 2004-06-30 2015-12-23 Janssen Pharmaceutica NV Phthalazine derivatives as parp inhibitors
WO2006003148A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as parp inhibitors
ES2380702T3 (es) 2004-06-30 2012-05-17 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de PARP
US8003790B2 (en) * 2005-02-18 2011-08-23 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
EA016264B1 (ru) 2006-03-31 2012-03-30 Янссен Фармацевтика Н.В. Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
EP2215075B1 (en) 2007-10-26 2013-12-11 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp inhibitors
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
SG192446A1 (en) * 2008-06-30 2013-08-30 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
EP2376495A4 (en) 2008-12-08 2012-10-31 Vm Pharma Llc COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
US8987444B2 (en) * 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
US9708300B2 (en) * 2011-03-20 2017-07-18 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
MX342140B (es) * 2011-09-30 2016-09-14 Janssen Pharmaceutica Nv Sal clorhidrato cristalina de (1-(4-fluorofenil)-1h-indol-5-il)-(3 -(4-(tiazol-2-carbonil)piperazin-1-il) azetidin-1-il)metanona y su uso en el tratamiento del dolor y transtornos metabolicos.
CA2866852C (en) * 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
RU2711077C9 (ru) 2012-03-15 2020-08-11 Селджен Кар Ллс Соли ингибитора киназы рецептора эпидермального фактора роста
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
HRP20200253T1 (hr) 2013-03-06 2020-05-29 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
WO2015084649A1 (en) * 2013-12-03 2015-06-11 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
MA39286A (fr) 2014-09-17 2016-03-24 Mundipharma International Corporation Ltd Formes cristallines d'inhibiteurs de la tyrosine kinase et leurs sels
CN108884072B (zh) * 2016-03-22 2020-12-22 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) * 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
US3301855A (en) * 1963-04-22 1967-01-31 Ciba Geigy Corp Derivatives of 4-nu-(2-nu, nu-dimethylaminolower alkyl)-amino quinazoline
DE1249281B (enExample) * 1963-05-18
US3257400A (en) * 1964-06-10 1966-06-21 Searle & Co 2-amino-5, 6-dihydrobenzo[h]quinazolin-4(3h)-one and congeners

Also Published As

Publication number Publication date
DE1620127C3 (de) 1974-10-10
GB1062357A (en) 1967-03-22
GB1174272A (en) 1969-12-17
DE1620127A1 (de) 1970-03-12
GB1174273A (en) 1969-12-17
US3609152A (en) 1971-09-28
BE678216A (enExample) 1966-09-22
DE1620127B2 (de) 1974-01-17

Similar Documents

Publication Publication Date Title
FR5267M (enExample)
JPS5010908B1 (enExample)
JPS4124986Y1 (enExample)
JPS442948Y1 (enExample)
JPS4319306Y1 (enExample)
JPS4411880Y1 (enExample)
BE675023A (enExample)
BE676151A (enExample)
BE676049A (enExample)
BE675968A (enExample)
BE675916A (enExample)
BE674859A (enExample)
BE675877A (enExample)
BE675837A (enExample)
BE675802A (enExample)
BE675780A (enExample)
BE675762A (enExample)
BE675757A (enExample)
BE675751A (enExample)
BE675298A (enExample)
BE675244A (enExample)
BE675241A (enExample)
BE675179A (enExample)
BE675174A (enExample)
BE676074A (enExample)